EASi-HF Trial facts

Participants will receive the trial medication for about **1.5 years (17 months)** and up to about **3.5 years (42 months)**.

Participants will take the trial medication, by mouth, **once a day** in the morning at the same time.

All participants will also continue to receive their standard-of-care treatment for HF.

About **6000** adults will take part in the trial across the world.

An Institutional Review Board (IRB)/Ethics Committee (EC) protects the rights, safety, and well-being of trial participants. An IRB/EC has reviewed this trial.

6000 adults

Who can take part?

You may be able to take part if you:

- are 18 years of age or older
- have been diagnosed with chronic HF at least 3 months ago and have a LVEF of at least 40% (we can measure this when we look to see if you can participate)
- are already receiving treatment for your HF.

Other factors to consider

A group of doctors, nurses, and other medical staff (the site staff) will:

- explain the possible risks and benefits of the trial
- carefully monitor the health of participants
- provide the trial medication and trial-related tests at no cost.

Participants will not be paid to take part in this trial. They may be paid back (reimbursed) for reasonable time and travel costs.

Taking part in a clinical trial is an important decision. Make sure you ask all the questions you have before deciding whether to take part.

How do I get more information?

Trial participation is voluntary. If you contact us, you do not have to take part in the trial.

Please scan the QR code to visit the website and learn more about the trial.

www.EASi-HFtrial.com

Patient Brochure, 02 Apr 2024 [V01 Global(en)]

Join heart failure research

Put a whole team behind you

Our clinical trial is looking for a better way to treat people with heart failure. Join us today.

Trial Information

A trial for people with chronic heart failure (HF)

EASi-HF

What is a clinical research trial?

A clinical research trial is a medical trial that helps to answer important questions about an investigational medication, such as:

- Does it work?
- How safe is it?
- What are the side effects?
- Does it affect people differently based on their age, gender, race, and/or ethnicity?

Clinical research trials test possible new medications. The results of these trials are crucial to whether medications receive approval to be given to patients.

People may experience HF in different ways. We work to make sure that our trials include people of different races, ethnicities, genders, ages, and backgrounds. This helps us to see how medications work for different people who are impacted by HF.

About the EASi-HF Trial

The EASi-HF Trial is looking at a potential new treatment option for people with chronic HF who have left ventricular ejection fraction (LVEF) of 40% or higher. This potential new treatment option is a combination of an investigational medication with an approved medication for HF.

This trial is looking to find out if this combination is effective and safe for people with HF and LVEF of 40% or higher, who are already receiving the best possible "standard-of-care" treatment.

The investigational combination will be compared with a placebo in combination with the approved medication in addition to standard-of-care treatment. A placebo does not contain any active ingredients.

What does LVEF mean?

Left ventricular ejection fraction (also referred to as LVEF) measures how well the heart pumps blood, and how much blood is pumped out of the left lower chamber (ventricle) of the heart to the body's organs.

LVEF is shown as a percentage. The percentage is a measurement of the amount of blood that the heart pumps out of the left ventricle into the body each time it beats.

An LVEF of about 50–70% is considered normal. An LVEF of about 40–50% is considered mildly abnormal, which means you have, or are at risk of developing, HF.



Tell me more about the trial

If you join this trial, you will continue to receive your existing best standard-of-care treatment. You will also be randomly assigned (by chance) to receive either the:

- investigational medication + approved medication, or
- placebo + approved medication.

You will not know which trial medication combination you are receiving.

The **investigational medication** is designed to stop the body from producing a hormone called aldosterone. Too much aldosterone in the body can cause high blood pressure, chronic kidney disease, or HF.

The **approved medication** is used to prevent cardiovascular events in adults with type 2 diabetes, and cardiovascular disease, HF, and chronic kidney disease.

The **placebo** looks like the investigational medication but does not contain any active ingredients.